The effect of zoledronic acid on type and volume of Modic changes among patients with low back pain

Table 2 Level and volume of the primary Modic change at baseline and follow-up and the change in the volume according to treatment group

Volume of the primary Modic change^a	Mean (SD)		Mean (SD) change			Age-adjusted analyses		Adjusted analyses
Volume of the primary Modic change^a	ZA n = 19	Placebo n = 20	ZA	Placebo	P^b	Difference (95% CI)	P^c	Difference (95% CI)	P^d
Level^a, n (%)
L2/3	4 (21.1)	0 (0.0)
L3/4	2 (10.5)	5 (25.0)
L4/5	6 (31.6)	5 (25.0)
L5/S1	7 (36.8)	10 (50.0)
Volume of M1^a (cm³)
Baseline	7.37 (4.58)	5.04 (3.55)
Follow-up	6.54 (5.38)	5.95 (4.46)	-0.83 (4.44)	0.91 (4.02)	0.21	−1.79 (−4.58, 1.00)	0.20	−1.92 (−5.03, 1.19)	0.22
Volume of M2^a (cm³)
Baseline	4.53 (4.00)	5.87 (4.84)
Follow-up	6.94 (4.57)	7.84 (6.78)	2.40 (2.95)	1.97 (4.20)	0.71	0.34 (−2.07, 2.74)	0.78	0.232 (−2.44, 2.90)	0.86
Total volume^a (cm³)
Baseline	11.90 (5.27)	10.91 (5.96)
Follow-up	13.48 (5.55)	13.79 (6.64)	1.58 (2.24)	2.88 (3.92)	0.21	−1.45 (−3.55, 0.64)	0.17	−1.69 (−4.14, 0.76)	0.17

SD standard deviation, CI confidence interval, ZA zoledronic acid
^aThe primary Modic change was assumed to cause patients’ symptoms at baseline
^bChange in the volume compared between the treatment groups, significance from the independent samples t-test
^cAnalysis of covariance for change in the volume compared between the treatment groups, adjusted for age
^dAnalysis of covariance for change in the volume compared between the treatment groups, adjusted for age, sex, Body Mass Index, and smoking

ISSN: 1471-2474